What GLP-1 sellers do not publish
Four things a reader has to know before buying a GLP-1 online, counted across every seller this site has read. Each one is an absence with a denominator attached, and none of them is a company’s fault printed as a verdict — it is what the page did not say on the day it was read.
Ellis Brandt built this site’s grading methodology and maintains it. Last re-read September 2026.
How this was counted
60 sellers, each read from its own public pages and dated September 2026. A seller counts as publishing something only if a reader can see it: terms that exist in a page’s markup but never render are counted as absent, and 4 of the 60 sellers whose figure states what it buys are in exactly that state for their cancellation terms. A control a reader can operate — an accordion, a collapsed panel — counts as published, because a control that reveals text is a reader reaching it.
This site holds 117 sellers in all. The other 57 publish 151 rankable monthly figures between them and not one of those figures says what dose it buys, so none of the four counts above was read on them — their cancellation terms were never opened and their figures have no stated basis. Counting them in either half would be an absence with the wrong census attached. Each of the 57 has its own page saying what was read and what was not, under every seller we have read.
No provider is named on this page and no link on it is paid. Every finding below is stated per seller, with its read date, on that seller’s own page under every seller we have read.
Never name the dispensing pharmacy
54 of 60
Never say compounded or branded
34 of 60
Do not print the dose schedule
54 of 60
No cancellation terms a reader can reach
36 of 60
Read from each seller’s own public pages, September 2026. Counted from the records this site publishes; see how we grade.
The pharmacy that would dispense
54 of the 60 sellers whose figure states what it buys never name the pharmacy that would dispense the prescription. 6 do.
It is the single most common silence on this roster, and it is the one a reader can do least about. The seller you buy from is usually not the entity that compounds or ships the drug; without the pharmacy’s name there is nothing to look up — no state board record, no inspection history, no way to tell whether two sellers at very different prices are shipping from the same facility.
6 of the 60 sellers whose figure states what it buys appear to share an operator with another seller on this roster — the same corporate footprint behind two brand names. That is recorded per seller rather than asserted here, because a shared registrant is a candidate and not a finding.
Compounded or branded
34 of the 60 sellers whose figure states what it buys do not state, beside the price, whether the drug being sold is compounded or the branded product. 26 say compounded. None on this roster says branded.
The two are not the same product and they are not regulated the same way. A compounded drug is prepared by a pharmacy rather than approved by the FDA as a finished product, and the difference is the reason a figure can be a fraction of the branded list price. A page that prints the figure and not the class has published the number that persuades and withheld the fact that explains it.
This site treats “the page does not say” as a value rather than a gap: it is what the seller published, and it is selectable as its own filter on every board.
The dose schedule
54 of the 60 sellers whose figure states what it buys do not print the titration steps their own patients follow. 6 do.
Every GLP-1 starts low and steps up, and where a seller charges by dose the schedule is also the price schedule — so a reader who cannot see the steps cannot work out what month four costs. What the four FDA-approved labels set as the escalation is published on this site with no provider named and no paid link, which is the closest a reader can get when the seller will not say.
Share of the 60 sellers whose figure states what it buys. Each seller is counted once, on the figure this site prints.
Computed from the one figure each seller publishes whose basis it states, September 2026.
How to cancel
36 of the 60 sellers whose figure states what it buys publish no cancellation terms a reader can reach. 24 do. Of the ones that do not, 4 carry the terms in their page’s markup without ever rendering them — text no reader can see, which this site counts as unpublished.
37 of the 60 sellers whose figure states what it buys claim a reader can cancel at any time. 16 of those publish no terms behind the claim — no route to cancel, no notice period, no refund position. That is not a silence; it is a promise with nothing under it.
Share of the 60 sellers whose figure states what it buys.
Read from each seller’s own pages, September 2026.
What they do publish
All 60 of the 60 sellers whose figure states what it buys publish a figure whose basis they state — what the money buys, in the seller’s own words — which is what this site requires before it will print a price at all. 59 of those figures are readable on a public page; one is published only inside an intake, and is marked as such on the board.
52 of the 60 sellers whose figure states what it buys state that the medication itself is included in the figure; 8 do not. 100 of the 60 sellers whose figure states what it buys carry the figure on a page a reader can reach directly, rather than only on a home page.
These are the four things this site scores. What each one is worth, and why, is on how we grade. No letter grade or ranking is published here: the weights are provisional and are not signed off.
Where the same records are compared
One board per buying decision. Each is the same table with the columns that decision needs, under its own dated and counted title.
- Semaglutide providers54 listed, September 2026
Readers who have settled on semaglutide and are choosing who to buy it from.
- Tirzepatide providers52 listed, September 2026
Readers who have settled on tirzepatide and are choosing who to buy it from.
- Providers that publish a price before the intake59 listed, September 2026
Readers who will not start an intake without seeing a standing rate and what it covers.
- GLP-1 providers with a published price, compared59 listed, September 2026
Readers whose first question is the number, and who want to see what each figure actually buys before comparing them.
- GLP-1 providers for readers paying cash52 listed, September 2026
Readers who are paying out of pocket and need the medication itself inside the published figure, not just the consult.
- GLP-1 telehealth providers60 listed, September 2026
Readers choosing a prescriber rather than a price — who dispenses, what the plan includes, and how to leave it.
What the FDA labels say
The four sub-scores on this site measure what a seller publishes — not the drug. What each drug is approved to treat, how its dose escalates and who should not take it is read from the FDA-approved prescribing information, with no provider named and no paid link.
- Semaglutide vs tirzepatidereading the label
What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.
- Dose escalation schedulesreading the label
The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.
- Side effect ratesreading the label
What each label reports for nausea, vomiting, diarrhoea and constipation — and the sentence every label prints above those numbers.
- Missed dose rulesreading the label
The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.
- Drug interactionsreading the label
Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.
- Buying one onlinereading the label
The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.
- Who should not take onereading the label
The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.